$CATX

Perspective Therapeutics (CATX) received FDA Fast Track Designation for PSV359, a treatment for FAP-positive solitary fibrous tumors. The therapy targets FAP-α, a protein linked to aggressive cancers, with limited current treatment options. The FDA program aims to expedite development and review for serious conditions with unmet medical needs.

Perspective Therapeutics (NYSE: CATX) will present clinical data on its [212Pb]VMT-α-NET program for advanced neuroendocrine tumors at the NANETS 2026 symposium. The company is developing radiopharmaceutical treatments using alpha-emitting isotopes to target cancer cells. Interim data was previously presented at the 2026 ASCO meeting, with additional data planned for future conferences. The company is also advancing other clinical-stage programs in the U.S.

Perspective Therapeutics (CATX) announced that data from its [212Pb]VMT01 program will be presented at the SITC 2026 Annual Meeting. The program targets metastatic melanoma and showed promising results in a phase I/IIa trial, with two responders out of seven patients in the 3.0 mCi monotherapy cohort. The drug was well-tolerated with no dose-limiting toxicities.

Perspective Therapeutics, Inc. (CATX) filed an SEC Form 8-K — Other Events. Next-Generation Radiopharmaceuticals Redefining Targeted Oncology Designed to be the Most Potent Payload in Targeted Oncology Three Independent Clinical-Stage Programs, Each Against a Distinct Target with Data in 2026 Deep Leadership Across Radiopharmaceutical and Drug Developmen

Novo Nordisk (NVO) shares fell 4.8% to $41.15 in pre-market trading after Phase 3 trial results. Other stocks moving lower include Aligos Therapeutics (ALGS) down 15.1%, Telix Pharmaceuticals (TLX) down 7.9%, and Li Auto (LI) down 3.5%.

Analyst Andy Hsieh of William Blair initiated coverage on Perspective Therapeutics (CATX) with an Outperform rating, citing its potential in radiopharmaceutical cancer treatments. The firm estimates a fair value of $11.45 per share, significantly higher than its recent closing price of $2.70. Hsieh highlights a $35 billion market opportunity in the U.S. for radiopharmaceuticals, driven by sector growth and Perspective's lead-212-based platform. The stock was trading at $2.86 at the time of publi

Lantheus Alpha Therapy, LLC sold 247,932 shares of Perspective Therapeutics, Inc. (CATX) at an average of $3.13 ($3.11–$3.15, $0.78M total) across 2 trades over 2026-09-03 to 2026-09-04. Filed jointly with Lantheus Holdings, Inc. (10% owner).

Lantheus Alpha Therapy, LLC sold 42,129 shares of Perspective Therapeutics, Inc. (CATX) at $3.11 ($0.13M total) on 2026-09-02. Filed jointly with Lantheus Holdings, Inc. (10% owner).

Lantheus Alpha Therapy, LLC sold 113,914 shares of Perspective Therapeutics, Inc. (CATX) at an average of $3.14 ($3.12–$3.14, $0.36M total) across 2 trades over 2026-08-31 to 2026-09-01.

Perspective Therapeutics (CATX) disclosed that Lantheus Holdings, a 10% owner, sold 35,769 shares at an average price of $3.12, retaining 11.6M shares indirectly. The sale was not part of a 10b5-1 trading plan.